Cancer Cachexia Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Pfizer, Aveo Oncology, Extend Biosciences, GTx, Akamis Bio, Centocor, Inc., AEterna Zentaris, Helsinn Therapeutics

DelveInsight's "Cancer Cachexia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Cancer Cachexia, historical and forecasted epidemiology as well as the Cancer Cachexia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Cancer Cachexia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cancer Cachexia Market Forecast
https://www.delveinsight.com/sample-request/cancer-cachexia-cc-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Cancer Cachexia Market Report:
• The Cancer Cachexia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• Aoyagi et al.'s Japanese study, "Cancer cachexia, mechanism and treatment," states that 22% of cancer patients die from cachexia, which affects most terminal cancer patients.
• About 70% of cancer patients have cachexia, according to the Cancer Cachexia Hub. In the final two weeks of life, this rate of incidence can reach 86%, and 45% of patients lose more than 10% of their initial body weight as the disease progresses.
• A study by Lim et al. (2020) found that between 22% and 30% of cancer-related fatalities are caused by cancer cachexia, which affects about 80% of cancer patients.
• At the moment, cytokine-based therapeutic methods, anabolic steroids, and nutritional counseling or appetite stimulants are the possible treatment choices for cancer cachexia.
• Key Cancer Cachexia Companies: Actimed Therapeutics, Pfizer, Aveo Oncology, Extend Biosciences, GTx, Akamis Bio, Centocor, Inc., AEterna Zentaris, Helsinn Therapeutics, Acacia Pharma, Helsinn Therapeutics, Novartis, Vicus Therapeutics, Celgene, CSL Behring, Helsinn Therapeutics, and others
• Key Cancer Cachexia Therapies: ACM-001, PF 06946860, AV-380, EXT418, GTx-024, MT-102, Infliximab; Gemcitabine, Macimorelin, RC-1291, APD209, RC-1291, BYM338, VT-122, Lenalidomide, ALD518, Anamorelin HCl, and others
• The Cancer Cachexia epidemiology based on gender analyzed that through various secondary studies it can be concluded that cancer cachexia affects both males and females equally
• The Cancer Cachexia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cancer Cachexia pipeline products will significantly revolutionize the Cancer Cachexia market dynamics.

Cancer Cachexia Overview
A wasting illness known as cancer cachexia is typified by anemia, asthenia, anorexia (lack of appetite), and weight loss. This syndrome's multifaceted pathogenicity results from the intricate interplay between host and tumor components. Patients with advanced cancer, chronic heart failure, rheumatoid arthritis, chronic infection, including AIDS and tuberculosis, and chronic obstructive pulmonary disease are among those who experience it.

Get a Free sample for the Cancer Cachexia Market Report
https://www.delveinsight.com/report-store/cancer-cachexia-cc-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cancer Cachexia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Cancer Cachexia Epidemiology Segmentation:
The Cancer Cachexia market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Cancer Cachexia
• Prevalent Cases of Cancer Cachexia by severity
• Gender-specific Prevalence of Cancer Cachexia
• Diagnosed Cases of Episodic and Chronic Cancer Cachexia

Download the report to understand which factors are driving Cancer Cachexia epidemiology trends @ Cancer Cachexia Epidemiology Forecast
https://www.delveinsight.com/sample-request/cancer-cachexia-cc-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cancer Cachexia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cancer Cachexia market or expected to get launched during the study period. The analysis covers Cancer Cachexia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Cancer Cachexia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cancer Cachexia Therapies and Key Companies
• ACM-001: Actimed Therapeutics
• PF 06946860: Pfizer
• AV-380: Aveo Oncology
• EXT418: Extend Biosciences
• GTx-024: GTx
• MT-102: Akamis Bio
• Infliximab; Gemcitabine: Centocor, Inc.
• Macimorelin: AEterna Zentaris
• RC-1291: Helsinn Therapeutics
• APD209: Acacia Pharma
• RC-1291: Helsinn Therapeutics
• BYM338: Novartis
• VT-122: Vicus Therapeutics
• Lenalidomide: Celgene
• ALD518: CSL Behring
• Anamorelin HCl: Helsinn Therapeutics

Discover more about therapies set to grab major Cancer Cachexia market share @ Cancer Cachexia Treatment Market
https://www.delveinsight.com/sample-request/cancer-cachexia-cc-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cancer Cachexia Market Strengths
• ADLUMIZ (Anamorelin) was recently approved in Japan for the treatment of this condition.

Cancer Cachexia Market Opportunities
• The lack of effective therapies for this condition provides a great opportunity for companies to develop treatment for cachexia, as there is less competition in the market.

Scope of the Cancer Cachexia Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Cancer Cachexia Companies: Actimed Therapeutics, Pfizer, Aveo Oncology, Extend Biosciences, GTx, Akamis Bio, Centocor, Inc., AEterna Zentaris, Helsinn Therapeutics, Acacia Pharma, Helsinn Therapeutics, Novartis, Vicus Therapeutics, Celgene, CSL Behring, Helsinn Therapeutics, and others
• Key Cancer Cachexia Therapies: ACM-001, PF 06946860, AV-380, EXT418, GTx-024, MT-102, Infliximab; Gemcitabine, Macimorelin, RC-1291, APD209, RC-1291, BYM338, VT-122, Lenalidomide, ALD518, Anamorelin HCl, and others
• Cancer Cachexia Therapeutic Assessment: Cancer Cachexia current marketed and Cancer Cachexia emerging therapies
• Cancer Cachexia Market Dynamics: Cancer Cachexia market drivers and Cancer Cachexia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Cancer Cachexia Unmet Needs, KOL's views, Analyst's views, Cancer Cachexia Market Access and Reimbursement

To know more about Cancer Cachexia companies working in the treatment market, visit @ Cancer Cachexia Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/cancer-cachexia-cc-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Cancer Cachexia Market Report Introduction
2. Executive Summary for Cancer Cachexia
3. SWOT analysis of Cancer Cachexia
4. Cancer Cachexia Patient Share (%) Overview at a Glance
5. Cancer Cachexia Market Overview at a Glance
6. Cancer Cachexia Disease Background and Overview
7. Cancer Cachexia Epidemiology and Patient Population
8. Country-Specific Patient Population of Cancer Cachexia
9. Cancer Cachexia Current Treatment and Medical Practices
10. Cancer Cachexia Unmet Needs
11. Cancer Cachexia Emerging Therapies
12. Cancer Cachexia Market Outlook
13. Country-Wise Cancer Cachexia Market Analysis (2019-2032)
14. Cancer Cachexia Market Access and Reimbursement of Therapies
15. Cancer Cachexia Market Drivers
16. Cancer Cachexia Market Barriers
17. Cancer Cachexia Appendix
18. Cancer Cachexia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Cancer Cachexia Pipeline https://www.delveinsight.com/report-store/cancer-cachexia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Cancer Cachexia Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Cancer Cachexia market. A detailed picture of the Cancer Cachexia pipeline landscape is provided, which includes the disease overview and Cancer Cachexia treatment guidelines.
Cancer Cachexia Epidemiology https://www.delveinsight.com/report-store/cancer-cachexia-cc-epidemiology-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Cancer Cachexia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cancer Cachexia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:

Iga Nephropathy Market
https://www.delveinsight.com/report-store/iga-nephropathy-market
DelveInsight's "IgA Nephropathy Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of the IgA Nephropathy, historical and forecasted epidemiology as well as the IgA Nephropathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China.

Vutrisiran Market
https://www.delveinsight.com/report-store/vutrisiran-market
DelveInsight's "Vutrisiran Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Vutrisiran, historical and forecasted epidemiology as well as the Vutrisiran market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Gastroesophageal Reflux Disease Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market
DelveInsight's "Gastroesophageal Reflux Disease (GERD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Gastroesophageal Reflux Disease (GERD), historical and forecasted epidemiology as well as the Gastroesophageal Reflux Disease (GERD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Cerebral Palsy Market
https://www.delveinsight.com/report-store/cerebral-palsy-market
DelveInsight's 'Cerebral Palsy Market Insights, Epidemiology, and Market Forecast 2032' report delivers an in-depth understanding of cerebral palsy, historical and forecasted epidemiology as well as cerebral palsy market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Granulomatosis With Polyangiitis Market
https://www.delveinsight.com/report-store/granulomatosis-with-polyangiitis-market
DelveInsight's "Granulomatosis With Polyangiitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Granulomatosis With Polyangiitis, historical and forecasted epidemiology as well as the Granulomatosis With Polyangiitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Hemophilia A Market
https://www.delveinsight.com/report-store/hemophilia-a2030-market
DelveInsight's "Hemophilia A Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Hemophilia A, historical and forecasted epidemiology as well as the Hemophilia A market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.